Revolution Medicines, Inc. Warrant
NASDAQ Global SelectTotal Valuation
Revolution Medicines, Inc. Warrant carries a market capitalization of 45.83B, placing it among publicly traded companies globally. Its enterprise value stands at -1.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 45.83B |
| Enterprise Value | -1.29B |
Share Statistics
Revolution Medicines, Inc. Warrant currently has 214.24M shares outstanding.
| Shares Outstanding | 214.24M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.77 |
| P/TBV Ratio | 0.79 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Financial Position
Revolution Medicines, Inc. Warrant maintains a current ratio of 11.38, meaning it holds 11.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 24.63, indicating elevated leverage, while an interest coverage ratio of -27.04 demonstrates limited ability to service its debt obligations.
| Current Ratio | 11.38 |
| Quick Ratio | 11.12 |
| Debt / Equity | 24.63 |
| Debt / EBITDA | -0.40 |
| Interest Coverage | -27.04 |
Financial Efficiency
| Return on Equity (ROE) | -79.09 |
| Return on Assets (ROA) | -52.37 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Revolution Medicines, Inc. Warrant's stock has gained approximately 2900% over the past 52 weeks. The 50-day moving average sits at 11.08, while the 200-day moving average is 6.31.
| Beta (5Y) | N/A |
| 52-Week Price Change | 2900% |
| 50-Day Moving Average | 11.08 |
| 200-Day Moving Average | 6.31 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -1.60B, while operating income came in at -1.63B.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -1.63B |
| Pretax Income | -1.77B |
| Net Income | -1.77B |
| EBITDA | -1.60B |
| EBIT | -1.63B |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Revolution Medicines, Inc. Warrant holds 3.94B in cash and equivalents against 641.93M in total debt, resulting in a net debt position of -328.00M. Total book value stands at 2.61B, with working capital of 3.67B providing operational flexibility.
| Cash & Cash Equivalents | 3.94B |
| Total Debt | 641.93M |
| Net Debt | -328.00M |
| Equity (Book Value) | 2.61B |
| Book Value Per Share | 12.16 |
| Working Capital | 3.67B |
Cash Flow
Revolution Medicines, Inc. Warrant produced -1.58B in operating cash flow over the past twelve months.
| Operating Cash Flow | -1.58B |
| Capital Expenditures | -10.64M |
| Free Cash Flow | -1.59B |
| FCF Per Share | N/A |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -162.32 |
| FCF Yield | N/A |
Scores
Revolution Medicines, Inc. Warrant posts an Altman Z-Score of -0.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.83 |